Evidence map›Paper›PMID 38480816›Full record

ArticleScientific reports2024

Impact of LKB1 status on radiation outcome in patients with stage III non-small-cell lung cancer.

Piyada Sitthideatphaiboon, Chonnipa Nantavithya, Poonchavist Chantranuwat, Chanida Vinayanuwattikun, Virote Sriuranpong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. TheCancer management and research · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Piyada SitthideatphaiboonDivision of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, 1873 Henry Dunant Rd, Pathumwan, Bangkok, 10330, Thailand.
Chonnipa NantavithyaDivision of Therapeutic Radiation and Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand.
Poonchavist ChantranuwatDepartment of Pathology, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand.
Chanida VinayanuwattikunDivision of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, 1873 Henry Dunant Rd, Pathumwan, Bangkok, 10330, Thailand.
Virote SriuranpongDivision of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, 1873 Henry Dunant Rd, Pathumwan, Bangkok, 10330, Thailand. vsmdcu40@gmail.com.
Chulalongkorn University · THKing Chulalongkorn Memorial Hospital · TH

Funding

Ratchadapiseksompotch Endowment Fund, Faculty of Medicine, Chulalongkorn University RA61/121
6 · The paper itself

Abstract

Preclinical studies suggest that loss of LKB1 expression renders cancer cells less responsive to radiation partly through NRF2-mediated upregulation of antioxidant enzymes protecting against radiation-induced DNA damage. Here we investigated the association of an alteration in this pathway with radio-resistance in lung cancer patients. Patients with locally advanced non-small cell lung cancer (LA-NSCLC) who were treated with chemoradiotherapy (CRT) and analyzed for LKB1 expression using semiquantitative immunohistochemistry. Clinical characteristics and expression of LKB1 were analyzed for association with radiotherapy outcomes. We analyzed 74 available tumor specimens from 178 patients. After a median follow-up of 40.7 months, 2-year cumulative incidence of locoregional recurrence (LRR) in patients who had LKB1

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAMP-Activated Protein Kinase KinasesBiomarkersChemoradiotherapyHumansNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesAMP-Activated Protein Kinase KinasesBiomarkersSTK11 protein, humanLiver kinase B1Locoregional recurrenceNon-small cell lung cancerNuclear factor erythroid 2-like 2Radiotherapy

Identifiers

PMID38480816
PMCPMC10938003
OpenAlexW4392815521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.